[1]许文,王阁,陈川,等.索拉菲尼诱导大鼠肝细胞癌形成过程中巨噬细胞和自然杀伤细胞的聚集[J].陆军军医大学学报(原第三军医大学学报),2009,31(11):1009-1012.
 XU Wen,WANG Ge,CHEN Chuan,et al.Sorafenib induces aggregation of macrophages and natural killer cells in hepatocellular carcinoma rats[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(11):1009-1012.
点击复制

索拉菲尼诱导大鼠肝细胞癌形成过程中巨噬细胞和自然杀伤细胞的聚集
(/HTML )
分享到:

陆军军医大学学报(原第三军医大学学报)[ISSN:1000-5404/CN:51-1095/R]

卷:
31卷
期数:
2009年第11期
页码:
1009-1012
栏目:
论著
出版日期:
2009-06-15

文章信息/Info

Title:
Sorafenib induces aggregation of macrophages and natural killer cells in hepatocellular carcinoma rats
作者:
许文王阁陈川张志敏李琼雒喜忠郑继军胡庆王东李增鹏
第三军医大学大坪医院野战外科研究所肿瘤中心
Author(s):
XU Wen WANG Ge CHEN Chuan ZHANG Zhi-min LI Qiong LUO Xi-zhong ZHENG Ji-jun HU Qing WANG Dong LI Zeng-peng
Cancer Center, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China
关键词:
索拉菲尼肝细胞癌CD68CD57CD34巨噬细胞自然杀伤细胞
Keywords:
Sorafenib hepatocellular carcinoma CD68 CD57  CD34 macrophage natural killer cells
分类号:
R73-36;R735.7;R967
文献标志码:
A
摘要:
目的   探讨多分子靶点药物索拉菲尼(Sorafenib)对肝细胞癌(hepatocellular carcinoma,HCC)形成过程中巨噬细胞标记物CD68和自然杀伤细胞标记物CD57的分布、表达情况的影响。   方法   改良法建立HCC模型,设立正常对照组(A组)、单纯模型组(B组)、早期单倍组(C组)、早期双倍组(D组)、晚期单倍组(E组)、晚期双倍组(F组),在HCC形成早期和晚期应用单、双倍剂量的索拉菲尼对C~F组进行干预,用免疫组织化学方法动态观察HCC组织中CD57、CD68和CD34的变化。   结果   B组CD57、CD68阳性细胞的数目逐渐增加,各个实验组(C~F组)分别在第12、14周时出现峰值后不同程度的减少,而D、F组在第18周后两者数目减少不明显,其中第20、22周时D、F组分别与B组相比均显著增加(P<0.05),同时D组比C组,F组比E组以及D组比F组亦显著增加(P<0.01, P<0.05),其余各组之间比较差异无统计学意义(P>0.05)。B组CD34阳性细胞数目逐渐增加,各个实验组(B~F组)在第16周后随诱癌时间延长有不同程度的减少,D组与C、E、F组相比亦显著减少(P<0.05)。   结论   索拉菲尼不仅可以抑制HCC组织的血管生成,还可以诱导HCC组织中的巨噬细胞和自然杀伤细胞的聚集,以早期双倍剂量组更明显,提示索拉菲尼治疗HCC的分子机制可能存在一种新的免疫调节机制,并呈剂量依赖性。
Abstract:
Objective   To study the effects of Sorafenib, a kind of multiple targeted agent, on the distribution and expression of CD68 and CD57, the markers of macrophages and natural killer cell during the course of hepatocellular carcinoma (HCC).     Methods   HCC model was established using improved method. The subjects were divided into six groups: blank control (group A), HCC model without intervention (group B), early stage HCC model with single dose of Sorafenib (group C), early stage HCC model with double dose of Sorafenib (group D), advanced stage with single dose (group E) and advanced stage with double dose (group F). The dynamic changes in CD57, CD68 and CD34 expressions from HCC tissues were detected immunohistochemically.     Results   Count of CD57 and CD68 positive cells in group B increased gradually, but the count of these cells in groups  C, D, E and F decreased at different degrees after the occurrence of the peak value at 12 and 14 weeks. No obvious change in the count of CD57 and CD68 positive cells was found in groups D and F at 18th week. At 20th and 22nd weeks, CD57 and CD68 positive cells in group D and F increased significantly as compared with those in group B (P<0.05), and the same result was found between groups D and C, groups F and E, and groups D and F (P<0.01, P<0.05). No significant difference was found between other groups. CD34 positive cells in group B increased gradually, but these cells in groups B, C, D, E and F decreased at 16th week in a time-dependent manner. Significant difference was found between group D and groups C, E and F (P<0.05).     Conclusion   Sorafenib can not only inhibit angiogenesis of HCC, but also induce the aggregation of macrophages and natural killer cells in HCC tissues, suggesting there might be a novel dose-dependent immunoregulatory mechanism in the molecular targeted therapy of HCC treatment with Sorafenib.

相似文献/References:

[1]宋春丽,任吉华,张祯祯,等.SIRT1基因沉默诱导肝癌细胞老化及其机制[J].陆军军医大学学报(原第三军医大学学报),2012,34(19):1929.
 Song Chunli,Ren Jihua,Zhang Zhenzhen,et al.Silent information regulator 1 gene induces aging of hepatocellular carcinoma cells via p53/p21 pathway[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(11):1929.
[2]李建国,江小杰.原发性肝癌RUNX3基因启动子区甲基化及其意义[J].陆军军医大学学报(原第三军医大学学报),2012,34(19):1933.
 Li Jianguo,Jiang Xiaojie.Methylation of RUNX3 gene promoter in HCC and its significance[J].J Amry Med Univ (J Third Mil Med Univ),2012,34(11):1933.
[3]左国华,梁平,李洪艳.肝细胞癌免疫磁珠的制备及鉴定[J].陆军军医大学学报(原第三军医大学学报),2005,27(16):1700.
[4]张小丽,高建,贾茜,等.肝癌干细胞样细胞的分离及其耐药性受PI3K/Akt通路调节[J].陆军军医大学学报(原第三军医大学学报),2013,35(02):99.
 Zhang Xiaoli,Gao Jian,Jia Qian,et al.Isolation of HCC cancer stem-like cells and chemo-resistance mediated by PI3K/Akt pathway[J].J Amry Med Univ (J Third Mil Med Univ),2013,35(11):99.
[5]潘光栋,严律南,王新平,等.RNA干扰逆转肝细胞癌多药耐药[J].陆军军医大学学报(原第三军医大学学报),2008,30(01):35.
 PAN Guang-dong,YAN Lu-nan,WANG Xin-ping,et al.Reversal of multidrug resistance of hepatocellular carcinoma by siRNA/mdr1[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(11):35.
[6]谢斌,唐春,吴刚,等.c-Met、MMP-2、MMP-9在肝细胞癌中的表达及临床意义[J].陆军军医大学学报(原第三军医大学学报),2008,30(12):1140.
 XIE Bin,TANG Chun,WU Gang,et al.Expressions and clinical significances of c-Met, MMP-2, MMP-9 in metastasis of human hepatocellular carcinoma: report of 47 cases[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(11):1140.
[7]廖翠薇,邹利光,卫静,等.实验性肝细胞癌SPIO增强MRI及其病理学对照研究[J].陆军军医大学学报(原第三军医大学学报),2006,28(01):38.
[8]李静,沈宜,杨麟,等.小鼠肝癌细胞(H22)源外泌体的体内抗肝癌作用研究[J].陆军军医大学学报(原第三军医大学学报),2008,30(19):1836.
 LI Jing,SHEN Yi,YANG Lin,et al.Antitumor effects of exosomes derived from a mouse hepatoma carcinoma cell line H22[J].J Amry Med Univ (J Third Mil Med Univ),2008,30(11):1836.
[9]张伟,杜成友,徐尔侃.肝癌临床发展与cyclin D1表达DNA含量及细胞凋亡发生的关系[J].陆军军医大学学报(原第三军医大学学报),2005,27(05):467.
[10]韩克强,吴娅利,黄小兵,等.Gankyrin蛋白在大鼠肝细胞癌变过程中的异常表达及意义[J].陆军军医大学学报(原第三军医大学学报),2009,31(11):1060.
 HAN Ke-qiang,WU Ya-li,HUANG Xiao-bing,et al.Abnormal expression and clinical significance of Gankyrin during hepatocarcinogenesis in rats[J].J Amry Med Univ (J Third Mil Med Univ),2009,31(11):1060.

更新日期/Last Update: 2009-05-21